Invasive Mucormycosis Induced Pneumopericardium: A Rare Cause of Pneumopericardium in an Immunocompromised Patient

Abstract

Mucor and Rhizopus cause life-threatening infections primarily involving the lungs and sinuses, which disseminate very rapidly by necrosis and infarction of the contiguous tissues. We present a case of a 64-year-old African American posttransplant patient who presented with a productive cough and weight loss. He had a past surgical history of renal transplant for renal cell carcinoma and was on dual immunosuppressive therapy, that is, mycophenolate and tacrolimus. During his hospital stay, he developed a pneumopericardium due to the direct extension of a lung lesion. The diagnosis was made by radiological imaging and PCR result which was consistent with Mucor species. He was treated with antifungal therapy. The purpose of this report is to highlight the unusual association of mucormycosis with pneumopericardium.

Mucormycosis in Indian COVID-19 Patients: Insight into Its Patho-Genesis, Clinical Manifestation, and Management Strategies

“…The lipid formulation of amphotericin-B (liposomal Am-B) is the first-line treatment for mucormycosis in COVID-19 patients. Injection of liposomal Am-B, with a starting dosage of 5–7.5 mg/kg/day, diluted in 500 mL of 5% dextrose over 4–5 h for 14–21 days, is commonly used in hospitalized adults and children [ 88 ]. Patients who are intolerant of or unresponsive to Am-B can be given alternative agents, such as an oral suspension of posaconazole, 400 mg two times a day or 200 mg four times a day.…”

Oral Isavuconazole Combined with Nebulized Inhalation and Bronchoscopic Administration of Amphotericin B for the Treatment of Pulmonary Mucormycosis: A Case Report and Literature Review

“…Rapid progress is a major characteristic of PM. Therefore, early diagnosis makes a significant difference in achieving a better prognosis and decreasing the need for surgery [ 34 , 35 ]. Generally, the diagnosis of mucormycosis relies on the availability of radiography-, histopathology-, culture-, and molecular-based methods [ 4 ].…”

Invasive Mediastinal Mucormycosis with Pulmonary and Cardiac Involvement in an Adult with Chronic Granulomatous Disease: Case Report and Review of the Literature

“…We performed a literature review of the period between the review of Cooper et al [7] and the present and identified three other cases. One was a patient who developed pneumopericardium and died [8] , a second case was a patient with a 7.2×5.4 cm mediastinal mass who received isavuconazonium sulfate and micafungin followed by surgical resection and survived [9] . The last case was a patient who initially had pulmonary mucormycosis which invaded the airways and mediastinal structures, causing a bronchomediastinal fistula and eventual death due to haemorrhage from pulmonary vasculature invasion [10] .…”